Evidence map›Paper›PMID 32960881›Full record

SynthesisPLoS medicine2020

Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.

Diana Buitrago-Garcia, Dianne Egli-Gany, Michel J Counotte, Stefanie Hossmann, Hira Imeri, Aziz Mert Ipekci, Georgia Salanti, Nicola Low

2 registry-linked trialsAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in PLoS medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 579 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
579citing papers in PubMed, 14 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04568356 nacompletednot on this map

A Clinical Performance Evaluation of the SARS-COV-2 Direct Antigen Rapid Test "DART"

TypeinterventionalSponsorE25Bio, Inc.Ran2020 to 2020Enrolled200ConditionsSARS CoV-2ArmsDirect Antigen Tests for COVID-19
NCT04742569 completednot on this map

Wearable Diagnostic for Detection of COVID-19 Infection

TypeobservationalSponsorClinOne, Inc.Ran2020 to 2022Enrolled790ConditionsCOVID-19
3 · Its place in the literature

Who cites it

579 citing papers in PubMed, 14 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Antiplatelet agents for the treatment of adults with COVID-19.The Cochrane database of systematic reviews · 2023
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Fluvoxamine for the treatment of COVID-19.The Cochrane database of systematic reviews · 2022
    Pooled it
  7. Pooled it
  8. Pooled it
  9. SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.The Cochrane database of systematic reviews · 2022
    Pooled it
  10. Janus kinase inhibitors for the treatment of COVID-19.The Cochrane database of systematic reviews · 2022
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article

519 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Diana Buitrago-GarciaInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0001-9761-206X
Dianne Egli-GanyInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0002-4725-0475
Michel J CounotteInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0003-1039-6873
Stefanie HossmannInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0003-1600-5925
Hira ImeriInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0002-0412-1649
Aziz Mert IpekciInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0002-0260-9691
Georgia SalantiInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0002-3830-8508
Nicola LowInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0003-4817-8986

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is disagreement about the level of asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We conducted a living systematic review and meta-analysis to address three questions: (1) Amongst people who become infected with SARS-CoV-2, what proportion does not experience symptoms at all during their infection? (2) Amongst people with SARS-CoV-2 infection who are asymptomatic when diagnosed, what proportion will develop symptoms later? (3) What proportion of SARS-CoV-2 transmission is accounted for by people who are either asymptomatic throughout infection or presymptomatic? METHODS AND

findingsWe searched PubMed, Embase, bioRxiv, and medRxiv using a database of SARS-CoV-2 literature that is updated daily, on 25 March 2020, 20 April 2020, and 10 June 2020. Studies of people with SARS-CoV-2 diagnosed by reverse transcriptase PCR (RT-PCR) that documented follow-up and symptom status at the beginning and end of follow-up or modelling studies were included. One reviewer extracted data and a second verified the extraction, with disagreement resolved by discussion or a third reviewer. Risk of bias in empirical studies was assessed with an adapted checklist for case series, and the relevance and credibility of modelling studies were assessed using a published checklist. We included a total of 94 studies. The overall estimate of the proportion of people who become infected with SARS-CoV-2 and remain asymptomatic throughout infection was 20% (95% confidence interval [CI] 17-25) with a prediction interval of 3%-67% in 79 studies that addressed this review question. There was some evidence that biases in the selection of participants influence the estimate. In seven studies of defined populations screened for SARS-CoV-2 and then followed, 31% (95% CI 26%-37%, prediction interval 24%-38%) remained asymptomatic. The proportion of people that is presymptomatic could not be summarised, owing to heterogeneity. The secondary attack rate was lower in contacts of people with asymptomatic infection than those with symptomatic infection (relative risk 0.35, 95% CI 0.10-1.27). Modelling studies fit to data found a higher proportion of all SARS-CoV-2 infections resulting from transmission from presymptomatic individuals than from asymptomatic individuals. Limitations of the review include that most included studies were not designed to estimate the proportion of asymptomatic SARS-CoV-2 infections and were at risk of selection biases; we did not consider the possible impact of false negative RT-PCR results, which would underestimate the proportion of asymptomatic infections; and the database does not include all sources.

conclusionsThe findings of this living systematic review suggest that most people who become infected with SARS-CoV-2 will not remain asymptomatic throughout the course of the infection. The contribution of presymptomatic and asymptomatic infections to overall SARS-CoV-2 transmission means that combination prevention measures, with enhanced hand hygiene, masks, testing tracing, and isolation strategies and social distancing, will continue to be needed.

Indexed as

Asymptomatic DiseasesAsymptomatic InfectionsBetacoronavirusCoronavirus InfectionsCOVID-19Disease ProgressionHumansMass ScreeningPandemicsPneumonia, ViralReverse Transcriptase Polymerase Chain ReactionSARS-CoV-2

Identifiers

PMID32960881
PMCPMC7508369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.